Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases



Zoster Vaccines Session: Introduction

ACIP Meeting June 25, 2021

Grace Lee, MD, MPH ACIP Chair, Herpes Zoster Work Group


Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.

2021 Herpes Zoster Work Group

ACIP Members	
Grace Lee, MD, MPH (Chair)	
Lynn Bahta, RN, MPH	
Camille Kotton, MD	
Ex Officio Members	
Paula Agger, MD, MPH	FDA
Jeffrey Cohen, MD	NIH
Darcie Everett, MD, MPH	FDA
Jeffrey Kelman, MD	CMS
Liaison Representatives	
Carol Baker, MD	IDSA
Mary Pat Friedlander, MD	AAFP
Sandra Fryhofer, MD	ACP/AMA
Elizabeth Rausch-Phung, MD, MPH	AIM
William Schaffner, MD	NFID
Kenneth Schmader, MD	AGS
Adam Welch, PharmD	APhA

Invited Consultants
Robin Avery, MD
Edward Belongia, MD
Al Benson, MD
Paul Cieslak, MD
Jeffrey Curtis, MD, MPH
Jay Fishman, MD
Rafael Harpaz, MD, MPH
Kelly Moore, MD, MPH
Vicki Morrison, MD
Steven Pergam, MD
Lisa Prosser, PhD
CDC Lead
Tara Anderson, DVM, MPH, PhD

Timeline of Recombinant Zoster Vaccine (RZV, Shingrix)



Abbreviations: HZ-Herpes Zoster; ZVL-Zoster Vaccine Live; RZV: Recombinant Zoster Vaccine; EtR-Evidence to Recommendations Framework

Policy question: "Should vaccination with RZV be recommended for immunocompromised adults 19 years of age and older?"

- Population: IC adults ≥19 years of age; split into two parts (19–49 years, ≥50 years)
- Intervention: RZV, 2 doses at least 4 weeks apart
- Comparison: No vaccine
- Outcomes

	Benefits	Harms
Critical	Prevent HZ	Serious adverse events
•	Prevent HZ-related hospitalization	Immune-mediated disease Reactogenicity (Grade 3) Graft versus host disease (HCT) Graft rejection (SOT)

Activities since February 2021 ACIP Meeting

- Six work group meetings
- Review and discussed
 - -GSK's Clinical Program regarding use of RZV in IC populations
 - -Economic assessments regarding use of RZV in IC populations

Agenda for Today's Session

 Burden of HZ in IC Adults

 Use of RZV in IC Populations:
Overview of
Clinical Program

Discussion

EtR Domain	Question	
Public Health Problem	Is the problem of public health importance?	
Benefits and Harms	How substantial are the desirable anticipated effects?	
	How substantial are the undesirable anticipated effects?	
	Do the desirable effects outweigh the undesirable effects?	
Values	Does the target population feel the desirable effects are	
	large relative to the undesirable effects?	
	Is there important variability in how patients value the	
	outcomes?	
Acceptability	Is the intervention acceptable to key stakeholders?	
Feasibility	Is the intervention feasible to implement?	
Resource Use	Is the intervention a reasonable and efficient allocation of	
	resources?	
Equity	What would be the impact of the intervention on health	
	equity?	

Acknowledgments

- ACIP HZWG: Paula Agger, Robin Avery, Lynn Bahta, Carol Baker, Edward Belongia, Al Benson, Paul Cieslak, Jeff Cohen, Jeff Curtis, Jeff Duchin, Darcie Everett, Jay Fishman, Mary Pat Friedlander, Sandra Fryhofer, Rafael Harpaz, Jeff Kelman, Camille Kotton, Vicki Morrison, Kelly Moore, Steve Pergam, Lisa Prosser, Elizabeth Rausch-Phung, Bill Schaffner, Ken Schmader, Adam Welch
- HZWG CDC Lead: Tara Anderson
- CDC, Other Contributors: Jessica Anderson, Stephanie Bialek, Tom Clark, Amanda Cohn, Kathleen Dooling, Jonathan Duffy, Richard Forshee, Angela Guo, Theresa Harrington, Alexandra Hess, Lisa Jackson, Jessica Leung, Shainoor Ismail, Tara Jatlaoui, Andrew Kroger, Andrew Leidner, Mona Marin, Karen Mason, Jennifer Nelson, Paul Rota, Ismael Ortega-Sanchez, Coleman Rotstein, Jeanne Santoli, Tom Shimabukuro, John Su, Megan Wallace, Eric Weintraub

Thank You

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

